Methods of use of anti-CD45 antibodies and conjugates thereof

A method of treating a human patient having a hematological cancer, the method comprising

• (a) administering to a human patient an antibody drug conjugate (ADC), in an amount sufficient to deplete a population of CD45+ cells in the patient, wherein the human patient has a hematological cancer;
• and
• (b) subsequently administering to the patient a transplant comprising hematopoietic stem cells,
• wherein the ADC comprises an anti-CD45 antibody, or an antigen-binding portion thereof, conjugated to a cytotoxin via a linker, wherein the cytotoxin is a DNA alkylating agent, and
• wherein the anti-CD45 antibody, or antigen-binding portion thereof comprises a heavy chain comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO:
• 42, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:43, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO:44;
• and a light chain comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO:
• 46, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:47;
• and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO:48.

A method of depleting a population of CD45+ cells in a human patient in need thereof, the method comprising administering to the patient an effective amount of an antibody drug conjugate (ADC),

• wherein the human patient has acute myeloid leukemia (AML) and is in need of a hematopoietic stem cell transplant,
• wherein the ADC comprises an anti-CD45 antibody, or an antigen-binding portion thereof, conjugated to a DNA alkylating agent via a linker, and
• wherein the anti-CD45 antibody, or antigen-binding portion thereof, comprises a heavy chain comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO:
• 42, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:43, and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO:44;
• and a light chain comprising a CDR1 domain comprising the amino acid sequence as set forth in SEQ ID NO:
• 46, a CDR2 domain comprising the amino acid sequence as set forth in SEQ ID NO:47;
• and a CDR3 domain comprising the amino acid sequence as set forth in SEQ ID NO:48.